Juvena Therapeutics focuses on harnessing the therapeutic potential of secreted proteins to restore tissue health and combat degenerative diseases. The company identifies and engineers biologics derived from a diverse library of proteins secreted by human stem cells. These proteins play a crucial role in cellular repair, tissue regeneration, and intercellular communication. Juvena's innovative approach addresses the dysregulation of protein signaling that occurs with aging or genetic mutations, which can lead to chronic diseases and loss of bodily functions. By mapping the therapeutic potential of these proteins, Juvena aims to develop life-saving treatments for conditions such as myopathies and metabolic diseases.

Central to Juvena's strategy is the JuvNET platform, an AI-enabled system that integrates various methodologies, including in silico mapping, in vitro screening, and in vivo pharmacology. This comprehensive approach allows for the efficient identification and development of novel biologic medicines. The platform leverages advanced technologies such as quantitative proteomics and robotics-enabled high-content imaging to enhance the discovery process. By continuously refining their protein library and utilizing AI for predictive modeling, Juvena is positioned to create transformative therapeutics that address muscular dystrophies and other metabolic disorders, ultimately aiming to improve health outcomes and quality of life for patients.

United States

Juvena Therapeutics is a biopharmaceutical company that focuses on developing innovative therapies for various medical conditions.

Genetic Diseases

Metabolic Diseases

Musculoskeletal Diseases

Nervous System Diseases

Juvena Therapeutics

Myotonic Dystrophy Type 1

JUV-161

Biologics

Duchenne muscular dystrophy

Muscle Atrophy

Obesity

JUV-149 & JUV-191

California - North

California

Artificial Intelligence

Protein Therapies

Regenerative Medicine

Stem Cells

Therapeutic

Juvena Therapeutics

Company Details